Harrison Hasanuddin, DO
Sleep Medicine · Monterey Park, CANPI 1790165785
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,412 of the $14,600 with a category attached, or 78.2%. 44 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 26.9% of the total. Reporting peaked in 2022 at $5,607 and has fallen 82.3% since, to $993 in 2025.
Across 385 payments — averaging $37.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$4K
- Amgen$1K
- AstraZeneca$1K
- Gilead$911
- AbbVie$892
- Lilly USA, LLC$836
- plus $6K from 38 others
What the payments were for
- Travel & lodging$3,08721%
- Food & beverage$11,41278%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,600 in reported general payments places this provider in the 85th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 130 | $128,115 |
| RybelsusSemaglutide | 48 | $93,590 |
| KerendiaFinerenone | 87 | $92,979 |
| CreonLipase/Protease/Amylase | 23 | $55,798 |
| JardianceEmpagliflozin | 54 | $52,731 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $50,926 |
| VascepaIcosapent Ethyl | 105 | $49,113 |
| JanuviaSitagliptin Phosphate | 40 | $39,088 |
| OzempicSemaglutide | 32 | $37,176 |
| EliquisApixaban | 26 | $33,161 |
| PrezcobixDarunavir/Cobicistat | 13 | $31,482 |
| LinzessLinaclotide | 29 | $30,600 |
| VemlidyTenofovir Alafenamide | 13 | $30,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $29,224 |
| Icosapent Ethyl | 62 | $22,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $1,107 | $139,470152 claims |
| Novo NordiskRybelsus, Ozempic | $652 | $130,76780 claims |
| BayerKerendia | $525 | $92,97987 claims |
| AbbVieCreon, Linzess | $892 | $86,39852 claims |
| GileadBiktarvy, Vemlidy | $911 | $81,04226 claims |
| Johnson & JohnsonPrezcobix, Xarelto, Invokana | $272 | $54,19847 claims |
| Boehringer IngelheimJardiance | $221 | $52,73154 claims |
| MerckJanuvia | $708 | $39,08840 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $374 | $34,91341 claims |
| PfizerEliquis | $288 | $33,16126 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $265 | $16,30625 claims |
| Lilly USA, LLCMounjaro | $836 | $14,31611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 200 sleep medicine providers in California.
Other sleep medicine in Monterey Park
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.1M
- Atul MalhotraSan Diego$771K
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Sam KashaniSanta Monica$221K
- Emmanuel MignotStanford$135K
- Jerome HesterPalo Alto$74K
- Mark BuchfuhrerDowney$70K
- Clete KushidaStanford$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.